Neurogene Inc. (NGNE) Current Ratio
- Current ratio · latest quarter: Value 10.64×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 10.64× | Current assets / current liabilities. $228.91M ÷ $21.50M ≈ 10.64× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 228.91M USD | Assets, Current |
| Current obligations | 21.50M USD | Liabilities, Current |
| Cash and equivalents | 112.48M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 3.29M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $228.91M | $21.50M | $112.48M | (m) | (m) | (m) | $3.29M | (m) | 10.64× |
| 2026-03-31 | $246.75M | $18.87M | $124.16M | (m) | (m) | (m) | $4.68M | (m) | 13.08× |
| 2025-12-31 | $271.77M | $16.41M | $103.84M | (m) | (m) | (m) | $1.95M | (m) | 16.56× |
| 2025-09-30 | $270.52M | $14.71M | $71.00M | (m) | (m) | (m) | $1.54M | (m) | 18.39× |
| 2025-06-30 | $278.99M | $15.44M | $58.81M | (m) | (m) | (m) | $2.06M | (m) | 18.07× |
| 2025-03-31 | $296.40M | $14.09M | $70.77M | (m) | (m) | (m) | $3.06M | (m) | 21.03× |
| 2024-12-31 | $315.92M | $15.16M | $136.59M | (m) | (m) | (m) | $1.34M | (m) | 20.84× |
| 2024-09-30 | $143.65M | $15.80M | $66.63M | (m) | (m) | (m) | $1.68M | (m) | 9.09× |
| 2024-06-30 | $159.15M | $13.07M | $111.03M | (m) | (m) | (m) | $1.72M | (m) | 12.17× |
| 2024-03-31 | $174.14M | $11.82M | $150.14M | (m) | (m) | (m) | $1.52M | (m) | 14.74× |
| 2023-12-31 | $200.35M | $22.97M | $148.21M | (m) | (m) | (m) | $2.60M | (m) | 8.72× |
| 2023-09-30 | $79.89M | $5.21M | $25.23M | $53.28M | (m) | (m) | (m) | (m) | 15.33× |
| 2023-06-30 | $83.78M | $4.88M | $31.11M | $50.95M | (m) | (m) | (m) | (m) | 17.17× |
| 2023-03-31 | $85.64M | $7.16M | $35.49M | $47.94M | (m) | (m) | (m) | (m) | 11.97× |
| 2022-12-31 | $84.72M | $6.65M | $82.02M | (m) | (m) | (m) | $625.00K | (m) | 12.74× |
| 2022-09-30 | $108.86M | $10.24M | $40.34M | $66.54M | (m) | (m) | (m) | (m) | 10.63× |
| 2022-06-30 | $118.48M | $9.27M | $77.53M | $38.93M | (m) | (m) | (m) | (m) | 12.78× |
| 2022-03-31 | $130.37M | $7.60M | $128.06M | (m) | (m) | (m) | (m) | (m) | 17.16× |
| 2021-12-31 | $143.99M | $8.64M | $142.47M | (m) | (m) | (m) | (m) | (m) | 16.67× |
| 2021-09-30 | $156.50M | $9.00M | $154.92M | (m) | (m) | (m) | (m) | (m) | 17.40× |
| 2021-06-30 | $167.50M | $7.58M | $164.24M | (m) | (m) | (m) | (m) | (m) | 22.09× |
| 2021-03-31 | $181.31M | $8.41M | $178.39M | (m) | (m) | (m) | (m) | (m) | 21.57× |
| 2020-12-31 | $194.52M | $7.89M | $192.56M | (m) | (m) | (m) | (m) | (m) | 24.66× |
| 2020-09-30 | $206.59M | $9.89M | $201.15M | (m) | (m) | (m) | (m) | (m) | 20.88× |
| 2020-06-30 | $131.00M | $6.32M | $129.60M | (m) | (m) | (m) | (m) | (m) | 20.73× |
| 2020-03-31 | $139.65M | $5.60M | $139.42M | (m) | (m) | (m) | (m) | (m) | 24.92× |
| 2019-12-31 | $143.60M | $4.74M | $143.09M | (m) | (m) | (m) | (m) | (m) | 30.28× |
| 2019-09-30 | $67.58M | $2.56M | $66.31M | (m) | (m) | (m) | (m) | (m) | 26.35× |
| 2019-06-30 | $73.21M | $1.16M | $72.70M | (m) | (m) | (m) | (m) | (m) | 63.17× |
| 2019-03-31 | $74.83M | $3.60M | $74.17M | (m) | (m) | (m) | (m) | (m) | 20.81× |
| 2018-12-31 | $77.17M | $4.63M | $76.93M | (m) | (m) | (m) | (m) | (m) | 16.68× |
| 2018-09-30 | $87.29M | $10.75M | $86.73M | $0.00 | (m) | (m) | (m) | (m) | 8.12× |
| 2018-06-30 | $103.24M | $13.35M | $99.13M | $3.01M | (m) | (m) | (m) | (m) | 7.73× |
| 2018-03-31 | $94.22M | $9.36M | $66.61M | $26.05M | (m) | (m) | (m) | (m) | 10.07× |
| 2017-12-31 | $108.83M | $10.96M | $52.03M | $56.05M | (m) | (m) | (m) | (m) | 9.93× |
| 2017-09-30 | $120.57M | $7.00M | $47.10M | $72.59M | (m) | (m) | (m) | (m) | 17.23× |
| 2017-06-30 | $132.19M | $8.13M | $27.15M | $104.13M | (m) | (m) | (m) | (m) | 16.26× |
| 2017-03-31 | $122.44M | $5.82M | $20.92M | $100.67M | (m) | (m) | (m) | (m) | 21.02× |
| 2016-12-31 | $103.48M | $9.52M | $32.30M | $70.76M | (m) | (m) | (m) | (m) | 10.87× |
| 2016-09-30 | $146.61M | $8.56M | $86.22M | $59.71M | (m) | (m) | (m) | (m) | 17.12× |
| 2016-06-30 | $67.65M | $8.50M | $22.47M | $44.09M | (m) | (m) | (m) | (m) | 7.96× |
| 2016-03-31 | $69.49M | $5.72M | $35.69M | $33.02M | (m) | (m) | (m) | (m) | 12.14× |
| 2015-12-31 | $74.80M | $4.79M | $39.53M | $34.96M | (m) | (m) | (m) | (m) | 15.61× |
| 2015-09-30 | $117.94M | $3.86M | $109.37M | $8.04M | (m) | (m) | (m) | (m) | 30.56× |
| 2015-06-30 | $29.76M | $3.98M | $14.92M | $14.11M | (m) | (m) | (m) | (m) | 7.47× |
| 2015-03-31 | $35.02M | $4.97M | $14.28M | $20.14M | (m) | (m) | (m) | (m) | 7.04× |
| 2014-12-31 | $39.30M | $5.20M | $14.91M | $24.19M | (m) | (m) | (m) | (m) | 7.55× |
| 2014-09-30 | $40.36M | $4.57M | $15.87M | $24.13M | (m) | (m) | (m) | (m) | 8.83× |
| 2014-06-30 | $36.34M | $2.85M | $17.90M | (m) | (m) | (m) | (m) | (m) | 12.77× |
| 2014-03-31 | $56.25M | $1.24M | $52.92M | (m) | (m) | (m) | (m) | (m) | 45.45× |
| 2013-12-31 | $15.30M | $2.62M | $11.01M | $2.82M | (m) | (m) | (m) | (m) | 5.84× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |